Cargando…
The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery”
Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, bioch...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947355/ https://www.ncbi.nlm.nih.gov/pubmed/31817815 http://dx.doi.org/10.3390/jcm8122165 |
_version_ | 1783485531289550848 |
---|---|
author | Romano, Giuseppe Vitale, Giuseppe Ajello, Laura Agnese, Valentina Bellavia, Diego Caccamo, Giuseppa Corrado, Egle Di Gesaro, Gabriele Falletta, Calogero La Franca, Eluisa Minà, Chiara Storniolo, Salvatore Antonio Sarullo, Filippo Maria Clemenza, Francesco |
author_facet | Romano, Giuseppe Vitale, Giuseppe Ajello, Laura Agnese, Valentina Bellavia, Diego Caccamo, Giuseppa Corrado, Egle Di Gesaro, Gabriele Falletta, Calogero La Franca, Eluisa Minà, Chiara Storniolo, Salvatore Antonio Sarullo, Filippo Maria Clemenza, Francesco |
author_sort | Romano, Giuseppe |
collection | PubMed |
description | Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 ± 10 years, 46% with ischemic heart disease) 205 (89%) completed the study. After a follow-up of 10.49 (2.93 ± 18.44) months, the percentage of patients in New York Heart Association (NYHA) class III changed from 40% to 17% (p < 0.001). Median N–Type natriuretic peptide (Nt-proBNP) decreased from 1865 ± 2318 to 1514 ± 2205 pg/mL, (p = 0.01). Furosemide dose reduced from 131.3 ± 154.5 to 120 ± 142.5 (p = 0.047). Ejection fraction (from 27± 5.9% to 30 ± 7.7% (p < 0.001) and E/A ratio (from 1.67 ± 1.21 to 1.42 ± 1.12 (p = 0.002)) improved. Moderate to severe mitral regurgitation (from 30.1% to 17.4%; p = 0.002) and tricuspid velocity decreased from 2.8 ± 0.55 m/s to 2.64 ± 0.59 m/s (p < 0.014). Conclusions: Sacubitril/valsartan induce “hemodynamic recovery” and, consistently with reduction in Nt-proBNP concentrations, improve NYHA class despite diuretic dose reduction. |
format | Online Article Text |
id | pubmed-6947355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69473552020-01-13 The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” Romano, Giuseppe Vitale, Giuseppe Ajello, Laura Agnese, Valentina Bellavia, Diego Caccamo, Giuseppa Corrado, Egle Di Gesaro, Gabriele Falletta, Calogero La Franca, Eluisa Minà, Chiara Storniolo, Salvatore Antonio Sarullo, Filippo Maria Clemenza, Francesco J Clin Med Article Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 ± 10 years, 46% with ischemic heart disease) 205 (89%) completed the study. After a follow-up of 10.49 (2.93 ± 18.44) months, the percentage of patients in New York Heart Association (NYHA) class III changed from 40% to 17% (p < 0.001). Median N–Type natriuretic peptide (Nt-proBNP) decreased from 1865 ± 2318 to 1514 ± 2205 pg/mL, (p = 0.01). Furosemide dose reduced from 131.3 ± 154.5 to 120 ± 142.5 (p = 0.047). Ejection fraction (from 27± 5.9% to 30 ± 7.7% (p < 0.001) and E/A ratio (from 1.67 ± 1.21 to 1.42 ± 1.12 (p = 0.002)) improved. Moderate to severe mitral regurgitation (from 30.1% to 17.4%; p = 0.002) and tricuspid velocity decreased from 2.8 ± 0.55 m/s to 2.64 ± 0.59 m/s (p < 0.014). Conclusions: Sacubitril/valsartan induce “hemodynamic recovery” and, consistently with reduction in Nt-proBNP concentrations, improve NYHA class despite diuretic dose reduction. MDPI 2019-12-06 /pmc/articles/PMC6947355/ /pubmed/31817815 http://dx.doi.org/10.3390/jcm8122165 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Romano, Giuseppe Vitale, Giuseppe Ajello, Laura Agnese, Valentina Bellavia, Diego Caccamo, Giuseppa Corrado, Egle Di Gesaro, Gabriele Falletta, Calogero La Franca, Eluisa Minà, Chiara Storniolo, Salvatore Antonio Sarullo, Filippo Maria Clemenza, Francesco The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” |
title | The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” |
title_full | The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” |
title_fullStr | The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” |
title_full_unstemmed | The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” |
title_short | The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The “Hemodynamic Recovery” |
title_sort | effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure with reduced ejection fraction: the “hemodynamic recovery” |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947355/ https://www.ncbi.nlm.nih.gov/pubmed/31817815 http://dx.doi.org/10.3390/jcm8122165 |
work_keys_str_mv | AT romanogiuseppe theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT vitalegiuseppe theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT ajellolaura theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT agnesevalentina theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT bellaviadiego theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT caccamogiuseppa theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT corradoegle theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT digesarogabriele theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT fallettacalogero theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT lafrancaeluisa theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT minachiara theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT storniolosalvatoreantonio theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT sarullofilippomaria theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT clemenzafrancesco theeffectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT romanogiuseppe effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT vitalegiuseppe effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT ajellolaura effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT agnesevalentina effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT bellaviadiego effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT caccamogiuseppa effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT corradoegle effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT digesarogabriele effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT fallettacalogero effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT lafrancaeluisa effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT minachiara effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT storniolosalvatoreantonio effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT sarullofilippomaria effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery AT clemenzafrancesco effectsofsacubitrilvalsartanonclinicalbiochemicalandechocardiographicparametersinpatientswithheartfailurewithreducedejectionfractionthehemodynamicrecovery |